CN106581098A - Medicinal composition for treating hip bone arthritis - Google Patents

Medicinal composition for treating hip bone arthritis Download PDF

Info

Publication number
CN106581098A
CN106581098A CN201611132991.4A CN201611132991A CN106581098A CN 106581098 A CN106581098 A CN 106581098A CN 201611132991 A CN201611132991 A CN 201611132991A CN 106581098 A CN106581098 A CN 106581098A
Authority
CN
China
Prior art keywords
weight
ethanol
pharmaceutical composition
weight portion
percent concentration
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
CN201611132991.4A
Other languages
Chinese (zh)
Inventor
不公告发明人
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Jinan Haoyu Qingtian Medicine Technology Co ltd
Original Assignee
Jinan Haoyu Qingtian Medicine Technology Co ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Jinan Haoyu Qingtian Medicine Technology Co ltd filed Critical Jinan Haoyu Qingtian Medicine Technology Co ltd
Priority to CN201611132991.4A priority Critical patent/CN106581098A/en
Publication of CN106581098A publication Critical patent/CN106581098A/en
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/421—1,3-Oxazoles, e.g. pemoline, trimethadione
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/20—Aceraceae (Maple family)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
    • A61K2236/30—Extraction of the material
    • A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
    • A61K2236/333—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using mixed solvents, e.g. 70% EtOH
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
    • A61K2236/30—Extraction of the material
    • A61K2236/39—Complex extraction schemes, e.g. fractionation or repeated extraction steps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
    • A61K2236/50—Methods involving additional extraction steps
    • A61K2236/55—Liquid-liquid separation; Phase separation

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Botany (AREA)
  • Engineering & Computer Science (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Biotechnology (AREA)
  • Medical Informatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Molecular Biology (AREA)
  • Medicines Containing Plant Substances (AREA)

Abstract

The invention discloses a medicinal composition for treating hip bone arthritis, and a preparation method thereof. The medicinal composition is prepared from twig and fruit of Acer grosseri Pax var. hersii (Rehd.) Rehd, Herb of Petrocosmea minor Hemsl., ephedroxane, eleutheroside E and nerolidol according to a certain ratio. The medicinal composition can be processed through routine preparation production technologies to form various dosage forms, and has a substantial treatment effect on the hip bone arthritis.

Description

The arthritic pharmaceutical composition for the treatment of hipbone
Technical field
The invention belongs to technical field of Chinese medicines, more particularly to one kind treats the arthritic pharmaceutical composition of hipbone and its system Preparation Method.
Background technology
Osteoarthritis (Osteoarthritis, OA) are a kind of common chronic joint diseases, and its major lesions is to close The degeneration and Secondary cases hyperosteogeny of section cartilage, is mainly in middle-aged and elderly people, is apt to occur in the joint for bearing a heavy burden larger (as hip is closed Section, knee joint, spinal column etc.)；The prevalence of osteoarthritis increases with age, the morbidity of China's osteoarthritis Rate is about 10%.Hip osteoarthritis (Hip Osteoarthritis) are one of concrete diseases in osteoarthritis, its Main clinical manifestation is to receive in hip pain, severe one hip joint flexing, compensatory kurtorachic, low back pain, or even can not Walking.Because hip osteoarthritis can have undesirable effect to the quality of life of patient, or even disable, therefore to hip osteoarthritis Carry out clinical research necessary.Be not fully apparent from yet about the pathogenesis of osteoarthritis, its mechanism may with decline Always, inflammation, cytokine exception, obesity, wound, joint excessively use, heredity, the correlation such as dysbolismus.Osteoarthritis Sickness rate is proportionate trend in being gradually increasing situation with the age, and it also has certain disability rate, so, close with regard to bone The scorching therapeutic potential of section is important and far-reaching.Current modern medicine is to the treatment of osteoarthritis without radical cure method, its primary treatment Method has:General treatment is (such as:Health education, sport healthcare), the topical medications (breast of various nonsteroidal antiinflammatory drugs Colloid, unguentum, patch, liniment etc.), whole body analgesic (such as:Acetaminophen, nonsteroidal antiinflammatory drug, opiatess town Pain agent etc.), improve state of an illness class medicine and Chondroprotective agents (such as:Glucosamine, diacerein, more chondroitin sulfate, west Ring element, Diphosphonate, vitamin A, vitamin C, Vitamin E, vitamin D etc.), joint cavity injection, surgical intervention etc.. The Therapeutic Method of above-mentioned modern medicine is due to there may be price, more potential toxic and side effects or risk (such as:Gastrointestinal tract is not Good reaction, hepatorenal damage, cardiovascular risk etc.) and the shortcoming such as curative effect is unstable and be difficult to be received completely by patient；The traditional Chinese medical science Pharmacy is the valuable medical science wealth of China, and extensive patients thirst for this kind of disease of Chinese medicine energy effectively treatment osteoarthritis, So from tcm field inquire into treatment osteoarthritis medicine and method for the treatment of highly significant.
Hip osteoarthritis can belong to the categories such as the traditional Chinese medical science " rheumatism involving the bone ", " myopathy ".This seminar is summarized by clinical observation Going out the arthritic pathogenesis of hipbone is probably:Patient's natural endowment is weak, or old or prolonged illness is big after being ill, causes vital essence virtual loss, kidney QI-insufficiency, skeleton loses and fills；Vital essence is lost, and space between skin and muscles is hollow, and joint is given away secrets, invades in wind-cold damp pathogen and cause cold coagulation stagnation of QI-blood, tendon and vessel Become estranged, numbness resistance in joint forms rheumatism involving the bone；Hyperosteogeny is to be attributed to kidney essense, deficiency of kidney-QI, and skeleton can not supplement nutrition and cause skeleton not just Chang Zengsheng, invades if any exopathogen or damages, and hypertrophy can be caused to become apparent from；Deficiency of kidney-essence, it is impossible to which metaplasia bone marrow essence and blood, bone is not Can be supplemented nutrition and cause skeleton weak and feeble, soreness of the waist and knees can be caused, be difficult to tolerate permanent standing；The spleen being located in middle-JIAO, main transporting, The cleer and peaceful system blood of liter, main limb muscle, the spleen being the foundation of acquired constitution, source of generating QI and blood are insufficiency of the spleen, transporting declines, on the one hand can shadow The supplement of kidney essense liver blood is rung, muscles and bones blood vessels is lost in taking good care of, on the other hand can cause water-damp not being transformed, turbid damp is cohesion, it is raw in phlegm retention, Flow in extremities joint, cause arthralgia, weigh, the disease such as morning stiffness, furthermore insufficiency of the spleen cause that atrophic debilities of the muscle is weak, directly affect limbs Joint motion.Therefore, the arthritic main pathogenesis characteristics of hipbone are blood stasis due to qi deficiency, belong to the card of deficiency in origin and excess in superficiality, related to spleen kidney, Therapeutic Method is when main with inrigorating qi and promoting blood circulation as method.
Moth tree：Pueraria lobota trailing plants maple Acer grosseri Pax var.hersii are split for Aceraceae Acer plants length（Rehd.） Rehd. the twig and fruit of ［ A.hersii Rehd. ］.9-10 month picking fruits, dry；The 6-7 months harvest twig, dry.【Property Taste】It is bitter；It is salty；It is flat.【Indication】Cough-relieving；Sore.The new chronic cough of master is coughed；Thrush.【Original shape state】It is tall that length splits Pueraria lobota trailing plants maple fallen leaves Wood, up to 8m.Bark is filbert, smooth；Annual shoot green or purple green, perennial branch lark or taupe, leaf opposite； The long 2-3cm of petiole, it is thin thin, without hair；Blade papery, avette, long 7-9cm, wide 5-6cm, edge has close and sharp heavy sawtooth, first Hold sharp point, base portion to be bordering on heart-shaped, often deeper 3 and split, central sliver is larger, and triangular shape is avette, above bottle green, without hair；Under Face light green, is then come off always in vein base portion when tender by faint yellow feathering；Base goes out 3, arteries and veins, lateral vein pinniform.Flower unisexuality, male and female are different Strain, often into thin thin sagging raceme；Sepal 5；Petal 5；Stamen 8, without hair, the aplasia in female flower；Floral disc is located at stamen Inner side；Ovary purple, the aplasia in male flower.The long 3-4mm of bennet.Lavender during Myriopteron extensum (Wight) K. Schum children, ripe rear yellowish-brown；Pyrene is micro- flat Flat, together with the long 2.5-2.9cm of pyrene, wide about 5mm or is bordering on level at flare up obtuse angle to wing.April at florescence, fruiting period September.Record In dictionary of medicinal plant.
Little Herba Hylotelephii Mingjiniani：For the complete of the little Herba Hylotelephii Mingjiniani Petrocosmea minor Hemsl. of Gesneriaceae Petrocosmea plant Grass.The 7-9 months harvest, and clean, and dry.Seed is little, oval, smooth.【Nature and flavor】Taste micro-pungent；It is mild-natured.【Indication】Dissipate wind-heat; Spleen invigorating removing food stagnancy.Main cold, fever；Infantile malnutrition.【Former phytomorph】The perennial Caulis et Folium Polygalae Tenuifoliae of little Herba Hylotelephii Mingjiniani acaulescence.Rhizome is short and thick, to Under close raw fibrous fibrous root.Phyllopodium gives birth to, 15-40 pieces;The leaf tool short handle of inner face or stockless, outside leaf tool handle, up to 4cm, close quilt The pubescence of shape swallowtail;Blade ellipticity whip shape, oval or subcircular, long 1-2.5cm, wide 8-15mm, the micro- point of tip, base portion Wide wedge shape or wedge shape, ellipse, full edge or have unconspicuous wavy little knuckle-tooth, green above leaf, below light green, the close quilt in two sides The pubescence of development.Flower 1-5 bars, there is 1 (- 2) flower per inflorescence;The long 3.5-7.5cm of peduncle, by development pubescence;Bract is narrow linear, 3mm is about, it is close by pubescence;Calyx 5 is split up to base portion, sliver wire lanceolar, and outside is by pubescence;Corolla purple, outside is by short soft Hair, corolla tube is short, long 2.5-3.5cm, is preced with the lip of mast two, upper lip ovate triangle, tip fine fisssure or nearly full edge, and lower lip 3 splits, sliver Near to wait big, tip is circular;Can educate stamen 2, filigree width floss shape, close by brown undercoat, flower pesticide is about 5mm, staminodium 2;Ovary Close to lie prostrate pubescence by patch, style is about 7mm, and, by short FUMAO, stigma is little, point-like for usual base portion.Capsule Long Circle, up to 10mm, By pubescence, room antiform is 2 lobes.Seed is little, oval, smooth.The month at florescence 8-9, the fruiting period 10-11 month.Record diction big in Chinese medicine Allusion quotation.
Nerolidol（Nerolidol）：CAS 7212-44-4, molecular formula C15H26O, molecular weight 222.37.【Composition comes Source】Rhizoma Zingiberis Recenss Zingiber officinale.
Eleutheroside E（Eleutheroside E）：CAS 96038-87-8, molecular formula C34H46O18, molecular weight 742.73.【Pharmacological action】Anti allergic reaction；Prevention prostate and atrophy of testis.【Ingredient origin】Acanthopanax sessiliflorus(Rupr.et Maxim.) Seem. skin Acanthopanax sessiliflorus。
Herba Ephedrae dislikes alkali（Ephedroxane ）：CAS 16251-46-0, molecular formula C11H13NO2, molecular weight 191.23.【Medicine Reason is acted on】With antiinflammatory action.【Ingredient origin】Ephedraceae ephedra root.
3 crude drug chemical constitutions：
Nerolidol（Nerolidol）
Eleutheroside E（Eleutheroside E）Herba Ephedrae dislikes alkali（Ephedroxane ）.
The content of the invention
The purpose of the present invention is to overcome the shortcomings of background technology, there is provided a kind of arthritic medicine group of effectively treatment hipbone Compound and preparation method thereof.
The present invention adopts the following technical scheme that realization：
The composition and weight portion for making the crude drug of the arthritic pharmaceutical composition for the treatment of hipbone be：
The little Herba Hylotelephii Mingjiniani 60-68 weight portions Herba Ephedrae of moth tree 85-90 weight portions dislikes alkali 4-8 weight portion eleutheroside E 2-3 weight Part nerolidol 1-2 weight portions.
The arthritic pharmaceutical composition for the treatment of hipbone is preferably used in, is made up of the crude drug of following weight portion：
The little weight portion Herba Ephedrae of Herba Hylotelephii Mingjiniani 64 of the weight portion of moth tree 88 dislikes the weight portion orange blossom uncle of 6 weight portion eleutheroside E of alkali 2.5 The weight portion of alcohol 1.5.
One kind treats the arthritic pharmaceutical composition of hipbone, it is characterised in that pharmaceutical composition can adopt galenic pharmacy Conventional method prepares piece agent or capsule or drop pill.
One kind treats the arthritic pharmaceutical composition of hipbone, it is characterised in that pharmaceutical composition and chemical drugs or Chinese medicine group Into treatment hip medicine for treating arthritis.
A kind of preparation method for treating the arthritic pharmaceutical composition of hipbone, it is characterised in that prepare as follows：
The composition and weight portion of crude drug be：The little Herba Hylotelephii Mingjiniani 60-68 weight portions Herba Ephedrae of moth tree 85-90 weight portions dislikes alkali 4-8 Weight portion eleutheroside E 2-3 weight portion nerolidol 1-2 weight portions；
Preparation method：
（1）Moth tree, little Herba Hylotelephii Mingjiniani, Herba Ephedrae are taken by crude drug proportioning and dislike alkali, eleutheroside E, nerolidol, mixed, use weight Used as solvent, 36.5 DEG C of warm macerating are extracted the ethanol of percent concentration 21%, and extraction time is 23 times, and each extraction time is 47 hours, Every time solvent load is 54 times of crude drug gross weight, filters, and obtains medicinal residues A and extracting solution A, and extracting solution A reclaims ethanol, is concentrated into Relative density 1.07, filtration, medicinal liquid is first washed with water by DM130B macroporous adsorptive resins, then uses weight percent concentration 18% ethanol solution eluting DM130B macroporous adsorptive resins, collect the ethanol elution of weight percent concentration 18%, reclaim ethanol, Concentrate drying, obtains final product extract A；
（2）Take step（1）Medicinal residues A, with the ethanol of weight percent concentration 53% as solvent, heating and refluxing extraction 23 times, carries every time The time is taken for 0.1 hour, each solvent load is 88 times of medicinal residues A weight, filters, obtain medicinal residues B and extracting solution B, extracting solution B is returned Ethanol is received, relative density 1.11 is concentrated into, is filtered, medicinal liquid is first washed with water by DM11 macroporous adsorptive resins, then uses weight The ethanol solution eluting DM11 macroporous adsorptive resins of percent concentration 82, collect the ethanol elution of weight percent concentration 82, return Ethanol is received, concentrate drying obtains final product extract B；
（3）Extract A and extract B are mixed, pharmaceutical composition is obtained final product.
Preferred a kind of preparation method for treating the arthritic pharmaceutical composition of hipbone, it is characterised in that as follows Prepare：
The composition and weight portion of crude drug be：The little weight portion Herba Ephedrae of Herba Hylotelephii Mingjiniani 64 of the weight portion of moth tree 88 dislikes the weight portion of alkali 6 thorn The weight portion of Acankoreoside A E2.5 weight portions nerolidol 1.5；
Preparation method：
（1）Moth tree, little Herba Hylotelephii Mingjiniani, Herba Ephedrae are taken by crude drug proportioning and dislike alkali, eleutheroside E, nerolidol, mixed, use weight Used as solvent, 36.5 DEG C of warm macerating are extracted the ethanol of percent concentration 21%, and extraction time is 23 times, and each extraction time is 47 hours, Every time solvent load is 54 times of crude drug gross weight, filters, and obtains medicinal residues A and extracting solution A, and extracting solution A reclaims ethanol, is concentrated into Relative density 1.07, filtration, medicinal liquid is first washed with water by DM130B macroporous adsorptive resins, then uses weight percent concentration 18% ethanol solution eluting DM130B macroporous adsorptive resins, collect the ethanol elution of weight percent concentration 18%, reclaim ethanol, Concentrate drying, obtains final product extract A；
（2）Take step（1）Medicinal residues A, with the ethanol of weight percent concentration 53% as solvent, heating and refluxing extraction 23 times, carries every time The time is taken for 0.1 hour, each solvent load is 88 times of medicinal residues A weight, filters, obtain medicinal residues B and extracting solution B, extracting solution B is returned Ethanol is received, relative density 1.11 is concentrated into, is filtered, medicinal liquid is first washed with water by DM11 macroporous adsorptive resins, then uses weight The ethanol solution eluting DM11 macroporous adsorptive resins of percent concentration 82, collect the ethanol elution of weight percent concentration 82, return Ethanol is received, concentrate drying obtains final product extract B；
（3）Extract A and extract B are mixed, pharmaceutical composition is obtained final product.
A kind of preparation method for treating the arthritic pharmaceutical composition of hipbone, it is characterised in that pharmaceutical composition can be adopted Piece agent or capsule or drop pill are prepared with the conventional method of galenic pharmacy.
A kind of preparation method for treating the arthritic pharmaceutical composition of hipbone, it is characterised in that pharmaceutical composition and chemistry Medicine or Chinese medicine composition treatment hip medicine for treating arthritis.
Medicine composite for curing hip osteoarthritis are evident in efficacy.
Specific embodiment
Embodiment 1：Arthritic pharmaceutical composition for the treatment of hipbone and preparation method thereof
The composition and weight portion of the crude drug of the treatment arthritic pharmaceutical composition of hipbone be：The little Herba Hylotelephii Mingjinianis of moth tree 88g 64g Herba Ephedraes dislike alkali 6g eleutheroside E 2.5g nerolidol 1.5g；
Preparation method：
（1）Moth tree, little Herba Hylotelephii Mingjiniani, Herba Ephedrae are taken by crude drug proportioning and dislike alkali, eleutheroside E, nerolidol, mixed, use weight Used as solvent, 36.5 DEG C of warm macerating are extracted the ethanol of percent concentration 21%, and extraction time is 23 times, and each extraction time is 47 hours, Every time solvent load is 54 times of crude drug gross weight, filters, and obtains medicinal residues A and extracting solution A, and extracting solution A reclaims ethanol, is concentrated into Relative density 1.07, filtration, medicinal liquid is first washed with water by DM130B macroporous adsorptive resins, then uses weight percent concentration 18% ethanol solution eluting DM130B macroporous adsorptive resins, collect the ethanol elution of weight percent concentration 18%, reclaim ethanol, Concentrate drying, obtains final product extract A；
（2）Take step（1）Medicinal residues A, with the ethanol of weight percent concentration 53% as solvent, heating and refluxing extraction 23 times, carries every time The time is taken for 0.1 hour, each solvent load is 88 times of medicinal residues A weight, filters, obtain medicinal residues B and extracting solution B, extracting solution B is returned Ethanol is received, relative density 1.11 is concentrated into, is filtered, medicinal liquid is first washed with water by DM11 macroporous adsorptive resins, then uses weight The ethanol solution eluting DM11 macroporous adsorptive resins of percent concentration 82, collect the ethanol elution of weight percent concentration 82, return Ethanol is received, concentrate drying obtains final product extract B；
（3）Extract A and extract B are mixed, pharmaceutical composition is obtained final product.
Embodiment 2：Arthritic pharmaceutical composition for the treatment of hipbone and preparation method thereof
The composition and weight portion of the crude drug of the treatment arthritic pharmaceutical composition of hipbone be：The little Herba Hylotelephii Mingjinianis of moth tree 85g 68g Herba Ephedraes dislike alkali 4g eleutheroside E 3g nerolidol 1g；
Preparation method：
（1）Moth tree, little Herba Hylotelephii Mingjiniani, Herba Ephedrae are taken by crude drug proportioning and dislike alkali, eleutheroside E, nerolidol, mixed, use weight Used as solvent, 36.5 DEG C of warm macerating are extracted the ethanol of percent concentration 21%, and extraction time is 23 times, and each extraction time is 47 hours, Every time solvent load is 54 times of crude drug gross weight, filters, and obtains medicinal residues A and extracting solution A, and extracting solution A reclaims ethanol, is concentrated into Relative density 1.07, filtration, medicinal liquid is first washed with water by DM130B macroporous adsorptive resins, then uses weight percent concentration 18% ethanol solution eluting DM130B macroporous adsorptive resins, collect the ethanol elution of weight percent concentration 18%, reclaim ethanol, Concentrate drying, obtains final product extract A；
（2）Take step（1）Medicinal residues A, with the ethanol of weight percent concentration 53% as solvent, heating and refluxing extraction 23 times, carries every time The time is taken for 0.1 hour, each solvent load is 88 times of medicinal residues A weight, filters, obtain medicinal residues B and extracting solution B, extracting solution B is returned Ethanol is received, relative density 1.11 is concentrated into, is filtered, medicinal liquid is first washed with water by DM11 macroporous adsorptive resins, then uses weight The ethanol solution eluting DM11 macroporous adsorptive resins of percent concentration 82, collect the ethanol elution of weight percent concentration 82, return Ethanol is received, concentrate drying obtains final product extract B；
（3）Extract A and extract B are mixed, pharmaceutical composition is obtained final product.
Embodiment 3：Arthritic pharmaceutical composition for the treatment of hipbone and preparation method thereof
The composition and weight portion of the crude drug of the treatment arthritic pharmaceutical composition of hipbone be：The little Herba Hylotelephii Mingjinianis of moth tree 90g 60g Herba Ephedraes dislike alkali 8g eleutheroside E 2g nerolidol 2g；
Preparation method：
（1）Moth tree, little Herba Hylotelephii Mingjiniani, Herba Ephedrae are taken by crude drug proportioning and dislike alkali, eleutheroside E, nerolidol, mixed, use weight Used as solvent, 36.5 DEG C of warm macerating are extracted the ethanol of percent concentration 21%, and extraction time is 23 times, and each extraction time is 47 hours, Every time solvent load is 54 times of crude drug gross weight, filters, and obtains medicinal residues A and extracting solution A, and extracting solution A reclaims ethanol, is concentrated into Relative density 1.07, filtration, medicinal liquid is first washed with water by DM130B macroporous adsorptive resins, then uses weight percent concentration 18% ethanol solution eluting DM130B macroporous adsorptive resins, collect the ethanol elution of weight percent concentration 18%, reclaim ethanol, Concentrate drying, obtains final product extract A；
（2）Take step（1）Medicinal residues A, with the ethanol of weight percent concentration 53% as solvent, heating and refluxing extraction 23 times, carries every time The time is taken for 0.1 hour, each solvent load is 88 times of medicinal residues A weight, filters, obtain medicinal residues B and extracting solution B, extracting solution B is returned Ethanol is received, relative density 1.11 is concentrated into, is filtered, medicinal liquid is first washed with water by DM11 macroporous adsorptive resins, then uses weight The ethanol solution eluting DM11 macroporous adsorptive resins of percent concentration 82, collect the ethanol elution of weight percent concentration 82, return Ethanol is received, concentrate drying obtains final product extract B；
（3）Extract A and extract B are mixed, pharmaceutical composition is obtained final product.
Embodiment 4：The preparation of tablet
The pharmaceutical composition 321g of Example 1, adds starch 417g, mixes, and granulation is dried, plus Microcrystalline Cellulose 150g, Hard Fat Sour magnesium 20g, mixes, and is pressed into 3800, obtains final product medicinal composition tablets.
Embodiment 5：The preparation of capsule
The pharmaceutical composition 320g of Example 2, adds starch 240g, mixes, and granulation is dried, granulate, adds appropriate stearic acid Magnesium, mixes, and encapsulated 2200, obtains final product medicament composition capsule.
Embodiment 6：The preparation of drop pill
Weigh (80 DEG C) heating of polyethylene glycol 6000 245g water-baths and boil molten, add the g of 3 pharmaceutical composition of embodiment 12, fully stir Mix uniform, with liquid paraffin as coolant, put glass tubing（4*80cm）In, chilling temperature is -4 DEG C, and drip internal-and external diameter is 7.0/ 2.0 (mm/mm), drip is 2.5cm away from liquid level, and drop speed, as optimum condition, with cotton the cold of drop pill surface is blotted with per point 53 drops Solidifying agent, obtains final product medicament composition dropping pills.
Embodiment 7：The arthritic pharmaceutical composition for the treatment of hipbone
The composition and weight portion of the crude drug of the treatment arthritic pharmaceutical composition of hipbone be：
Herba Ephedrae dislikes the weight portion of 30 weight portion eleutheroside E of alkali, 2 weight portion nerolidol 4.
Embodiment 8：The arthritic pharmaceutical composition for the treatment of hipbone
The composition and weight portion of the crude drug of the treatment arthritic pharmaceutical composition of hipbone be：
Herba Ephedrae dislikes the weight portion of 2 weight portion eleutheroside E of alkali, 10 weight portion nerolidol 1.
Embodiment 9：The arthritic pharmaceutical composition for the treatment of hipbone
The composition and weight portion of the crude drug of the treatment arthritic pharmaceutical composition of hipbone be：
Herba Ephedrae dislikes the weight portion of 10 weight portion eleutheroside E of alkali, 12 weight portion nerolidol 3.
Experimental example 1：The arthritic experimental study for the treatment of hipbone
1 object and method
1.1 object of study
1.1.1 diagnostic criteria and main inclusion criteria
Diagnostic criteria (the clinical and radiation that the diagnostic criteria of hip osteoarthritis is proposed for 1995 with reference to American society of rheumatism Standard), i.e.,:（1）The nearly 1 month hip arthralgia repeatedly；（2）Erythrocyte sedimentation rate≤20 mm/h；（3）X line pieces show that hyperosteogeny is formed, hip Mortar edge hypertrophy；（4）X line pieces show that hip joint space is narrow.Meet（1）+（2）+（3）Bar or（1）+（2）+（4）Bar or（1）+（3）+ （4）The diagnosable hip osteoarthritis of bar person.
This research is included 18～80 years old, meets the diagnostic criteria of hip osteoarthritis and sign to enter and study Informed Consent Form Patient.
1.1.2 main exclusion standard
Case inclusion criteria person is not met；Merge cardiovascular and cerebrovascular vessel, hemopoietic system, liver, hormonal system, kidney etc. serious primary Property disease and psychotic；Allergic constitution and to multiple medicines allergy sufferers；Pregnant suckling or the women of positive intended pregnancy；The state of an illness is endangered Weight, it is difficult to which definite estimator is made in the safety and effectiveness to new drug.
1.2 Therapeutic Method
Two groups of patients carry out health education, i.e.,:Need the arthritic ABC of hipbone is detailed to patient and its family members Inform, allow patient and its family members to recognize that disease is a chronic process and needs long-term treatment, actively to coordinate medical personnel Treatment, while the untoward reaction being likely to occur in therapeutic process should be paid close attention to and medical worker is informed in time.Two groups of patients enter Row R＆R is trained, i.e.,:Paathogenic factor is eliminated and avoided, mitigates joint load, such as lost weight, avoid damage to, use handss Cane, appropriate rest etc..The incremental rehabilitation training that hip joint function is actively carried out by patient is answered, is lived to keeping and improving joint Dynamic scope is beneficial.Matched group and treatment group carry out above-mentioned health education, R＆R training.
Matched group gives following Drug therapy:Meloxicam tablet (Chinese medicines quasi-word: H20020217):7.5mg/ time, 1 Times/day, one after each meal.
Treatment group gives pharmaceutical composition:The pharmaceutical composition of embodiment 1, each 0.8g is oral, daily 2 times, taking medicine after meal With.
Two groups with 2 months as 1 course for the treatment of, during test two groups disable any other treatment hip osteoarthritis Medicine or Therapeutic Method, two groups are continuously treated 2 months, and assess each group clinical efficacy respectively after 1 course for the treatment of terminates.
1.3 evaluation criterion
1.3.1 curative effect evaluation index
（1）Clinical symptoms, sign situation
Mainly there are the hip arthralgia, limited hip motion, morning stiffness, weak, twinge, the soft knee joint acid of shin, when curing syndrome integral in the calculation, Above-mentioned symptom is light, in, weight three-level scored respectively by 1 point, 2 points, 3 points.
（2）Lab index
Leading indicator includes erythrocyte sedimentation rate (Westergren ' s methods), C reactive proteins (simple immunodiffusion method) Deng.
1.3.2 untoward reaction observation
Examine two groups of patients over the course for the treatment of and impaired cardiac function, impaired lung function, erythra, Liver and kidney are whether there is after treatment and damage The untoward reaction of the aspects such as evil, gastrointestinal upset, impaired hematopoiesis occurs, and handles accordingly.
1.3.3 curative effect judging standard
Clinic control:The symptoms such as pain disappear, and joint motion is normal.
It is effective:The symptoms such as pain disappear, and joint motion is unrestricted.
Effectively:The symptoms such as pain are substantially eliminated, and joint motion is slightly limited.
It is invalid:The symptoms such as pain are not improved with joint motion.
1.4 statistical procedures
Using the statistical packages of SPSS 18.0, enumeration data adopts X 2 test, measurement data to check using t, P ＜ 0.05 to be considered as difference statistically significant.
2 results
2.1 physical data and clinical setting
This is studied is carried out in March, -2014 in March, 2012 in this city hospital rheumatism immunity section ward and outpatient service, according to research Plan is selected in altogether 42 hip Osteoarthritis, is randomized into matched group and treatment group is each 21.Matched group female 11, Man 10, minimal ages 33 years old, max age 66 years old, the mean age (45. 26 ± 11.54) year, the minimum course of disease 12 Month, the maximum course of disease 68 months, individual month of average course of disease (43.12 ± 10.42)；Treatment group female 11, man 10, minimal ages 32 Year, max age 66 years old, the mean age (44.41 ± 10.62) year, the minimum course of disease 11 months, the maximum course of disease 75 months, average disease Individual month of journey (44.26 ± 10.65).Two groups of no significant differences (P ＞ 0.05) in age, sex, the course of disease, two groups With comparability.Voluntarily Informed Consent Form, and further consultation as scheduled are treated in signature to all patients.
The comparison of 2.2 two groups of overall clinical efficacy rates
Table 1 shows that total effective rate compares after two groups of treatments, and difference has statistical significance (P ＜ 0.05), illustrates treatment group Clinical efficacy is better than matched group.
The comparative example (%) of total effective rate after 1 two groups of treatments of table ］
Group Number of cases Clinic control It is effective Effectively It is invalid Total effective rate/%
Matched group 21 3 5 5 8 61.90
Treatment group 21 6 7 6 2 90.48*
Note:Compare with matched group, * P ＜ 0.05.
Each clinical symptoms, sign improve the comparison of situation before and after 2.3 two groups of treatments
As a result show, each clinical symptoms integration no significant difference (P ＞ 0.05), respectively face after two groups of treatments before two groups of treatments Bed symptom has clinical symptoms improvement after significant improvement (P ＜ 0.05), and treatment group's treatment to be substantially better than matched group (P ＜ 0.05)。
The comparison of erythrocyte sedimentation rate and the change of C reactive proteins before and after 2.4 two groups of treatments
As a result show, two groups for the treatment of proerythrocyte sedimentation rates, no significant differences (P ＞ 0.05) of c reactive protein, two groups Erythrocyte sedimentation rate, c reactive protein have erythrocyte after significant improvement (P ＜ 0.05), and treatment group's treatment to sink after treatment Drop rate, c reactive protein improve degree and are considerably better than matched group (P ＜ 0.05).C reactive proteins improve degree and are considerably better than control Group (P ＜ 0.05).
2.5 untoward reaction
It is without exception at aspects such as cardiac function, pulmonary function, hepatic and renal function, hemopoietic functions before and after two groups of patient's treatments.Matched group has 2 There is xerostomia and constipation in example, and vague epigastralgia is uncomfortable and blood pressure is slightly raised to have 1 to occur, after above-mentioned uncomfortable row anti symptom treatment by Gradually take a turn for the better or disappear.Treatment group has no adverse reaction.

Claims (8)

1. one kind treats the arthritic pharmaceutical composition of hipbone, it is characterised in that make the group of the crude drug of the pharmaceutical composition It is into weight portion：
The little Herba Hylotelephii Mingjiniani 60-68 weight portions Herba Ephedrae of moth tree 85-90 weight portions dislikes alkali 4-8 weight portion eleutheroside E 2-3 weight Part nerolidol 1-2 weight portions.
2. according to claim 1 one kind treats the arthritic pharmaceutical composition of hipbone, it is characterised in that make the medicine The composition and weight portion of the crude drug of compositionss be：
The little weight portion Herba Ephedrae of Herba Hylotelephii Mingjiniani 64 of the weight portion of moth tree 88 dislikes the weight portion orange blossom uncle of 6 weight portion eleutheroside E of alkali 2.5 The weight portion of alcohol 1.5.
3. according to claim 1 one kind treats the arthritic pharmaceutical composition of hipbone, it is characterised in that pharmaceutical composition The conventional method that galenic pharmacy can be adopted prepares piece agent or capsule or drop pill.
4. according to claim 1 one kind treats the arthritic pharmaceutical composition of hipbone, it is characterised in that pharmaceutical composition The treatment hip medicine for treating arthritis constituted with chemical drugs or Chinese medicine.
5. a kind of preparation method for treating the arthritic pharmaceutical composition of hipbone, it is characterised in that prepare as follows：
The composition and weight portion of crude drug be：The little Herba Hylotelephii Mingjiniani 60-68 weight portions Herba Ephedrae of moth tree 85-90 weight portions dislikes alkali 4-8 Weight portion eleutheroside E 2-3 weight portion nerolidol 1-2 weight portions；
Preparation method：
（1）Moth tree, little Herba Hylotelephii Mingjiniani, Herba Ephedrae are taken by crude drug proportioning and dislike alkali, eleutheroside E, nerolidol, mixed, use weight Used as solvent, 36.5 DEG C of warm macerating are extracted the ethanol of percent concentration 21%, and extraction time is 23 times, and each extraction time is 47 hours, Every time solvent load is 54 times of crude drug gross weight, filters, and obtains medicinal residues A and extracting solution A, and extracting solution A reclaims ethanol, is concentrated into Relative density 1.07, filtration, medicinal liquid is first washed with water by DM130B macroporous adsorptive resins, then uses weight percent concentration 18% ethanol solution eluting DM130B macroporous adsorptive resins, collect the ethanol elution of weight percent concentration 18%, reclaim ethanol, Concentrate drying, obtains final product extract A；
（2）Take step（1）Medicinal residues A, with the ethanol of weight percent concentration 53% as solvent, heating and refluxing extraction 23 times, carries every time The time is taken for 0.1 hour, each solvent load is 88 times of medicinal residues A weight, filters, obtain medicinal residues B and extracting solution B, extracting solution B is returned Ethanol is received, relative density 1.11 is concentrated into, is filtered, medicinal liquid is first washed with water by DM11 macroporous adsorptive resins, then uses weight The ethanol solution eluting DM11 macroporous adsorptive resins of percent concentration 82, collect the ethanol elution of weight percent concentration 82, return Ethanol is received, concentrate drying obtains final product extract B；
（3）Extract A and extract B are mixed, pharmaceutical composition is obtained final product.
6. a kind of preparation method for treating the arthritic pharmaceutical composition of hipbone according to claim 5, it is characterised in that Prepare as follows：
The composition and weight portion of crude drug be：The little weight portion Herba Ephedrae of Herba Hylotelephii Mingjiniani 64 of the weight portion of moth tree 88 dislikes the weight portion of alkali 6 thorn The weight portion of Acankoreoside A E2.5 weight portions nerolidol 1.5；
Preparation method：
（1）Moth tree, little Herba Hylotelephii Mingjiniani, Herba Ephedrae are taken by crude drug proportioning and dislike alkali, eleutheroside E, nerolidol, mixed, use weight Used as solvent, 36.5 DEG C of warm macerating are extracted the ethanol of percent concentration 21%, and extraction time is 23 times, and each extraction time is 47 hours, Every time solvent load is 54 times of crude drug gross weight, filters, and obtains medicinal residues A and extracting solution A, and extracting solution A reclaims ethanol, is concentrated into Relative density 1.07, filtration, medicinal liquid is first washed with water by DM130B macroporous adsorptive resins, then uses weight percent concentration 18% ethanol solution eluting DM130B macroporous adsorptive resins, collect the ethanol elution of weight percent concentration 18%, reclaim ethanol, Concentrate drying, obtains final product extract A；
（2）Take step（1）Medicinal residues A, with the ethanol of weight percent concentration 53% as solvent, heating and refluxing extraction 23 times, carries every time The time is taken for 0.1 hour, each solvent load is 88 times of medicinal residues A weight, filters, obtain medicinal residues B and extracting solution B, extracting solution B is returned Ethanol is received, relative density 1.11 is concentrated into, is filtered, medicinal liquid is first washed with water by DM11 macroporous adsorptive resins, then uses weight The ethanol solution eluting DM11 macroporous adsorptive resins of percent concentration 82, collect the ethanol elution of weight percent concentration 82, return Ethanol is received, concentrate drying obtains final product extract B；
（3）Extract A and extract B are mixed, pharmaceutical composition is obtained final product.
7. a kind of preparation method for treating the arthritic pharmaceutical composition of hipbone according to claim 5, it is characterised in that Pharmaceutical composition can adopt the conventional method of galenic pharmacy to prepare piece agent or capsule or drop pill.
8. a kind of preparation method for treating the arthritic pharmaceutical composition of hipbone according to claim 5, it is characterised in that Pharmaceutical composition and chemical drugs or Chinese medicine composition treatment hip medicine for treating arthritis.
CN201611132991.4A 2016-12-10 2016-12-10 Medicinal composition for treating hip bone arthritis Withdrawn CN106581098A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201611132991.4A CN106581098A (en) 2016-12-10 2016-12-10 Medicinal composition for treating hip bone arthritis

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN201611132991.4A CN106581098A (en) 2016-12-10 2016-12-10 Medicinal composition for treating hip bone arthritis

Publications (1)

Publication Number Publication Date
CN106581098A true CN106581098A (en) 2017-04-26

Family

ID=58598462

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201611132991.4A Withdrawn CN106581098A (en) 2016-12-10 2016-12-10 Medicinal composition for treating hip bone arthritis

Country Status (1)

Country Link
CN (1) CN106581098A (en)

Similar Documents

Publication Publication Date Title
CN100471508C (en) Medicine for treating cardiac and cerebral vascular diseases and its prepn process
CN106581098A (en) Medicinal composition for treating hip bone arthritis
CN105287921A (en) Medicinal composition for treating gastric cancer and preparation method thereof
CN104687032A (en) Health caring echinacea health product
CN104367878A (en) Traditional Chinese medicine ointment for treating tinea of feet and hands and preparing method thereof
CN104740079A (en) Phyllanthus emblica health-care traditional Chinese medicine composition
CN104705634A (en) Lucid ganoderma healthcare product for protecting health
CN106540003A (en) A kind of pharmaceutical composition for treating hyperosteogeny
CN104147481B (en) A kind of antipruritic external medicine composition and preparation method thereof
CN106692244A (en) Pharmaceutical composition for treating hip osteoarthritis
CN105663248A (en) Depression treating pharmaceutical composition
CN106540011A (en) The pharmaceutical composition of preventing and treating senile osteoporosis
CN100496522C (en) Medicinal composition containing propolis, preparation method and use thereof
CN1127968C (en) Oral powder medicine Xiaobaisan for treating leukotrichia and its preparation method
CN105664022A (en) Traditional Chinese medicine composition preparation for treating metrocarcinoma and preparing method of traditional Chinese medicine composition preparation
CN106074736A (en) A kind of pharmaceutical composition treating cerebral thrombosis and preparation method thereof
CN105267824A (en) Healthcare medicinal liquor with kidney tonifying function
CN106581099A (en) Medicine composition for treating rheumatism
CN104645244A (en) Traditional Chinese medicine composition for treating atherosclerosis
CN104306467B (en) A kind of medicament treating hyperlipidemia
CN106581326A (en) Pharmaceutical composition for preventing and treating senile osteoporosis
CN116808128A (en) Traditional Chinese medicine composition for treating knee osteoarthritis and preparation method and application thereof
TWI535447B (en) Herbal extract for inhibiting growth of tumor
CN106539992A (en) It is a kind of to prevent and treat pharmaceutical composition of synovitis and preparation method thereof
CN106540012A (en) A kind of pharmaceutical composition for treating senile osteoporosis

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
WW01 Invention patent application withdrawn after publication
WW01 Invention patent application withdrawn after publication

Application publication date: 20170426